<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Psychopharmacology (Berl)</journal-id><journal-id journal-id-type="iso-abbrev">Psychopharmacology (Berl.)</journal-id><journal-title-group><journal-title>Psychopharmacology</journal-title></journal-title-group><issn pub-type="ppub">0033-3158</issn><issn pub-type="epub">1432-2072</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28551713</article-id><article-id pub-id-type="pmc">5519645</article-id><article-id pub-id-type="publisher-id">4643</article-id><article-id pub-id-type="doi">10.1007/s00213-017-4643-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group></article-categories><title-group><article-title>Atomoxetine effects on attentional bias to drug-related cues in cocaine dependent individuals</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Passamonti</surname><given-names>Luca</given-names></name><address><phone>+44.01223.330293</phone><email>lp337@medschl.cam.ac.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Luijten</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ziauddeen</surname><given-names>H.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Coyle-Gilchrist</surname><given-names>I. T. S.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rittman</surname><given-names>T.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Brain</surname><given-names>S. A. E.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Regenthal</surname><given-names>R.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Franken</surname><given-names>I. H. A.</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Sahakian</surname><given-names>B. J.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Bullmore</surname><given-names>E. T.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Robbins</surname><given-names>T. W.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Ersche</surname><given-names>K. D.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000000121885934</institution-id><institution-id institution-id-type="GRID">grid.5335.0</institution-id><institution>Departments of Clinical Neurosciences, </institution><institution>University of Cambridge, </institution></institution-wrap>Cambridge, CB2 0SZ UK </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1789 9809</institution-id><institution-id institution-id-type="GRID">grid.428490.3</institution-id><institution>Consiglio Nazionale delle Ricerche, </institution><institution>Istituto di Bioimmagini e Fisiologia Molecolare, </institution></institution-wrap>Catanzaro, Italy </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000000122931605</institution-id><institution-id institution-id-type="GRID">grid.5590.9</institution-id><institution>Behavioural Science Institute, </institution><institution>Radboud University, </institution></institution-wrap>Nijmegen, Netherlands </aff><aff id="Aff4"><label>4</label>Cambridgeshire and Peterborough Foundation Trust, Cambridge, UK </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2230 9752</institution-id><institution-id institution-id-type="GRID">grid.9647.c</institution-id><institution>Division of Clinical Pharmacology, Rudolf-Boehm-Institute of Pharmacology and Toxicology, </institution><institution>University of Leipzig, </institution></institution-wrap>Leipzig, Germany </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000000092621349</institution-id><institution-id institution-id-type="GRID">grid.6906.9</institution-id><institution>Institute of Psychology, </institution><institution>Erasmus University Rotterdam, </institution></institution-wrap>Rotterdam, Netherlands </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000000121885934</institution-id><institution-id institution-id-type="GRID">grid.5335.0</institution-id><institution>Behavioural and Clinical Neuroscience Institute, </institution><institution>University of Cambridge, </institution></institution-wrap>Cambridge, UK </aff><aff id="Aff8"><label>8</label>GlaxoSmithKline, Clinical Unit Cambridge, Cambridge, UK </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>27</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="ppub"><year>2017</year></pub-date><volume>234</volume><issue>15</issue><fpage>2289</fpage><lpage>2297</lpage><history><date date-type="received"><day>12</day><month>11</month><year>2016</year></date><date date-type="accepted"><day>11</day><month>5</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><sec><title>Rationale</title><p id="Par1">Biased attention towards drug-related cues and reduced inhibitory control over the regulation of drug-intake characterize drug addiction. The noradrenaline system has been critically implicated in both attentional and response inhibitory processes and is directly affected by drugs such as cocaine.</p></sec><sec><title>Objectives</title><p id="Par2">We examined the potentially beneficial effects of the noradrenaline reuptake inhibitor atomoxetine in improving cognitive control during two tasks that used cocaine- and non-cocaine-related stimuli.</p></sec><sec><title>Methods</title><p id="Par3">A double-blind, placebo-controlled, and cross-over psycho-pharmacological design was employed. A single oral dose of atomoxetine (40&#x000a0;mg) was administered to 28 cocaine-dependent individuals (CDIs) and 28 healthy controls. All participants performed a pictorial attentional bias task involving both cocaine- and non-cocaine-related pictures as well as a verbal go/no-go task composed of cocaine- and food-related words.</p></sec><sec><title>Results</title><p id="Par4">As expected, CDIs showed attentional bias to cocaine-related cues whilst controls did not. More importantly, however, atomoxetine, relative to placebo, significantly attenuated attentional bias in CDIs (<italic>F</italic>
<sub>26</sub>&#x000a0;=&#x000a0;6.73, <italic>P</italic>&#x000a0;=&#x000a0;0.01). During the go/no-go task, there was a treatment &#x000d7; trial &#x000d7; group interaction, although this finding only showed a trend towards statistical significance (<italic>F</italic>
<sub>26</sub>&#x000a0;=&#x000a0;3.38, <italic>P</italic>&#x000a0;=&#x000a0;0.07).</p></sec><sec><title>Conclusions</title><p id="Par5">Our findings suggest that atomoxetine reduces attentional bias to drug-related cues in CDIs. This may result from atomoxetine&#x02019;s modulation of the balance between tonic/phasic activity in the locus coeruleus and the possibly parallel enhancement of noradrenergic neurotransmission within the prefrontal cortex. Studying how cognitive enhancers such as atomoxetine influence key neurocognitive indices in cocaine addiction may help to develop reliable biomarkers for patient stratification in future clinical trials.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Attentional bias</kwd><kwd>Response inhibition</kwd><kwd>Cocaine addiction</kwd><kwd>Noradrenaline</kwd><kwd>Atomoxetine</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MR/J012084/1</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag GmbH Germany 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par6">Addiction to cocaine remains a significant public health problem, and with current treatment provision confined to psychosocial interventions, there is a pressing need to improve the breadth and nature of the therapeutic approaches to cocaine dependence (Goldstein et al. <xref ref-type="bibr" rid="CR25">2009</xref>; Lapeyre-Mestre and Dupui <xref ref-type="bibr" rid="CR30">2015</xref>; Wiessing <xref ref-type="bibr" rid="CR51">2005</xref>). There is also a consensus that enhancing our knowledge of the cognitive factors that underlie cocaine taking might help in developing new interventions to ameliorate the chances of recovery in cocaine-dependent individuals (CDIs).</p><p id="Par7">Cocaine-related cues capture the attention of CDIs and may influence their cocaine-taking behaviour (Marissen et al. <xref ref-type="bibr" rid="CR36">2006</xref>; Waters et al. <xref ref-type="bibr" rid="CR50">2012</xref>). Whilst performing cognitive tasks, CDIs, relative to controls, display biased attention towards distracting cocaine-related stimuli (Dunning et al. <xref ref-type="bibr" rid="CR14">2011</xref>; Ersche et al. <xref ref-type="bibr" rid="CR16">2010</xref>; Field et al. <xref ref-type="bibr" rid="CR18">2014</xref>; Goldstein et al. <xref ref-type="bibr" rid="CR24">2007</xref>; Hester et al. <xref ref-type="bibr" rid="CR27">2006</xref>; Leeman et al. <xref ref-type="bibr" rid="CR31">2014</xref>; Smith et al. <xref ref-type="bibr" rid="CR47">2013</xref>), although this &#x02018;attentional bias&#x02019; should not necessarily be considered to be abnormal per se as it can also be observed in healthy people even in the absence of any experimental manipulation (Pintzinger et al. <xref ref-type="bibr" rid="CR39">2016</xref>) or can be trained towards stimuli linked to salient and evolutionary important outcomes (Schmidt et al. <xref ref-type="bibr" rid="CR44">2016</xref>).</p><p id="Par8">The inhibitory control of maladaptive impulsive responses is another key mechanism that influences cocaine-taking behaviour; in other words, impulsivity represents a critical predictor of vulnerability for cocaine taking and relapse (Bosker et al. <xref ref-type="bibr" rid="CR6">2017</xref>; Ersche et al. <xref ref-type="bibr" rid="CR17">2012</xref>; Goldstein and Volkow <xref ref-type="bibr" rid="CR23">2002</xref>; Robbins et al. <xref ref-type="bibr" rid="CR40">2012</xref>). Although attentional bias and response disinhibition are distinct phenomena, attentional bias can clearly be influenced by cognitive control mechanisms including response inhibition (Bari and Robbins <xref ref-type="bibr" rid="CR4">2013</xref>). In particular, inhibitory mechanisms are fundamental in attentional tasks for limiting the amount of information accessible at any time and filtering out distracting environmental cues that may degrade behavioural performance (Bari and Robbins <xref ref-type="bibr" rid="CR4">2013</xref>).</p><p id="Par9">It follows that attenuating attentional bias to cocaine-related cues and potentiating response inhibition, via psychotherapy and/or pharmacotherapy, might help the development of new treatments to reduce cocaine-taking behaviour (Marhe et al. <xref ref-type="bibr" rid="CR35">2014</xref>). One potential approach could utilize pharmacological interventions to enable CDIs to recruit greater cognitive control to reduce attentional bias to cocaine-related cues and ameliorate response inhibition. An excellent candidate for this approach is atomoxetine, which inhibits the reuptake of noradrenaline in the synaptic cleft by blocking the noradrenaline transporter (Kratochvil et al. <xref ref-type="bibr" rid="CR29">2003</xref>). There is accumulating evidence that dysfunctioning noradrenergic transmission may be important in cocaine addiction (Schmidt and Weinshenker <xref ref-type="bibr" rid="CR43">2014</xref>), consistent with data from animal research showing that atomoxetine may attenuate the risk for relapse following cocaine abstinence (Economidou et al. <xref ref-type="bibr" rid="CR15">2011</xref>). However, a clinical trial that investigated the efficacy of atomoxetine in reducing cocaine use in CDIs was less promising than initial comparative studies (Walsh et al. <xref ref-type="bibr" rid="CR49">2013</xref>). Nevertheless, these are not necessarily conflicting findings, as drug taking and drug relapse have been shown to be separate processes that may involve distinct neural circuitry and, in many cases, can be differentially affected by pharmacotherapy. For example, both clinical and pre-clinical studies have shown that NET inhibitors may not be effective in decreasing ongoing drug use whilst other adrenergic agents (e.g. alpha 2 agonists) may reduce drug relapse (Fox and Sinha <xref ref-type="bibr" rid="CR20">2014</xref>; Fox et al. <xref ref-type="bibr" rid="CR21">2015</xref>; Smith and Aston-Jones <xref ref-type="bibr" rid="CR46">2011</xref>).</p><p id="Par10">Investigating how atomoxetine influences key neurocognitive markers such as attentional bias to cocaine-related cues and response inhibition in CDIs has therefore the potential to advance from purely descriptive accounts of behavioural problems to predictive and mechanistic models with the prospective for novel, rational, and individualized therapies. The main aim of this study was to test the hypothesis that a single dose of atomoxetine, relative to placebo, attenuates attentional bias to cocaine-related cues and potentiates response inhibition in CDIs. We employed two well-validated cognitive tasks that consistently index attentional bias and response inhibition (Chamberlain et al. <xref ref-type="bibr" rid="CR12">2009</xref>; Luijten et al. <xref ref-type="bibr" rid="CR33">2011</xref>; Noel et al. <xref ref-type="bibr" rid="CR38">2005</xref>). To elicit attentional bias to cocaine-related cues in CDIs, we adapted a task in which participants have to count the number of lines superimposed over distracting cocaine-related pictures (e.g. people smoking crack) (Luijten et al. <xref ref-type="bibr" rid="CR33">2011</xref>). The main advantage of this paradigm is that cocaine-related photographs evoke stronger reactions (thereby amplifying the attentional bias) in CDIs compared to the word stimuli typically used in Stroop tasks (Boyer and Dickerson <xref ref-type="bibr" rid="CR7">2003</xref>; Cane et al. <xref ref-type="bibr" rid="CR10">2009</xref>; Cox et al. <xref ref-type="bibr" rid="CR13">2006</xref>; Ryan <xref ref-type="bibr" rid="CR41">2002</xref>).</p><p id="Par11">Impulsivity and inhibitory control were assessed using a go/no-go task which included cocaine-related words as the main stimuli and control stimuli with motivational/appetitive salience (i.e. food-related words) (Noel et al. <xref ref-type="bibr" rid="CR38">2005</xref>). Atomoxetine (40&#x000a0;mg) has been found to potentiate response inhibition in healthy individuals (Chamberlain et al. <xref ref-type="bibr" rid="CR11">2006</xref>). Whilst some studies have failed to replicate this effect (Nandam et al. <xref ref-type="bibr" rid="CR37">2011</xref>) or have found opposite results (Graf et al. <xref ref-type="bibr" rid="CR26">2011</xref>), this might have&#x000a0;depended critically on the dose of atomoxetine; in the present study, we employed the optimal dose (40&#x000a0;mg) as used previously (Chamberlain et al. <xref ref-type="bibr" rid="CR11">2006</xref>).</p><p id="Par12">Finally, we explored whether and how clinical and personality variables (i.e. years of cocaine abuse, dysphoric mood, trait impulsivity) influenced the cognitive enhancing effects of atomoxetine (i.e. decreased attentional bias to cocaine-related cues and enhanced inhibitory control). Although we did not formally assess a possible diagnosis of attention-deficit/hyperactivity disorder (ADHD) using the DSM-IV criteria, the CDI individuals completed the adult ADHD Self-Report Scale (ASRS), which is a measure of individual differences in ADHD symptoms (Kessler et al. <xref ref-type="bibr" rid="CR28">2005</xref>). This is because previous evidence showed that atomoxetine may be useful in CDIs with ADHD symptoms (Levin et al. <xref ref-type="bibr" rid="CR32">2009</xref>).</p></sec><sec id="Sec2"><title>Participants and methods</title><sec id="Sec3"><title>Participants</title><p id="Par13">The study was approved by the National Research Ethics Committee and all participants provided written informed consent. Twenty-eight individuals who met the DSM-IV-TR criteria for cocaine dependence and 28 age- and gender-matched healthy controls with no history of dependence or other neuropsychiatric disorders took part in the study. Individuals with CDI were recruited via local treatment services and word of mouth. The healthy volunteers were recruited from the Cambridge BioResource volunteer panel (<ext-link ext-link-type="uri" xlink:href="http://www.cambridgebioresource.org.uk/">www.cambridgebioresource.org.uk</ext-link>).</p><p id="Par14">All participants were screened for medical and neuropsychiatric disorders by medical history, laboratory testing, physical examination, and electrocardiogram. Exclusion criteria for all participants were as follows: (1) any current or past serious medical illness such as hepatic, cardiac, renal, infectious, metabolic, or pulmonary disease; (2) any history of traumatic head injury; (3) pregnancy; (4) no proficiency in English; and (5) any involvement in a clinical trial investigating drug effects within the past 6&#x000a0;months. For controls, a personal history of any psychiatric disorder led to exclusion whilst for the cocaine group, a personal history of a psychotic disorder led to exclusion.</p><p id="Par15">All participants were screened for current psychiatric disorders using the Mini-International Neuropsychiatric Inventory (MINI) (Sheehan et al. <xref ref-type="bibr" rid="CR45">1998</xref>), and drug use was further evaluated using the Structured Clinical Interview for DSM-IV (SCID) (First <xref ref-type="bibr" rid="CR19">2002</xref>). Participants also completed the National Adult Reading Test (NART) to assess verbal intelligence quotient (IQ), the Beck Depression Inventory (BDI-II) to record dysphoric mood, the Spielberger State-Trait Anxiety Inventory (STAI) to evaluate anxiety levels, and the Barratt Impulsiveness Scale (BIS-11) to assess trait impulsivity. CDIs completed the obsessive-compulsive drug use scale (Franken et al. <xref ref-type="bibr" rid="CR22">2002</xref>) and the ASRS scale to assess for individual differences in ADHD symptoms (Kessler et al. <xref ref-type="bibr" rid="CR28">2005</xref>). Last, self-reported feelings of cocaine craving in CDIs were collected immediately after each testing session (i.e. placebo and atomoxetine).</p><p id="Par16">The attentional bias task to cocaine-related cues and go/no-go task were conducted at the Addenbrooke&#x02019;s Hospital in Cambridge (UK) in two separate sessions following a double-blinded design with a counterbalanced order across participants and treatment (i.e. atomoxetine, placebo). On each session, urine samples were analysed for cocaine. All the urine samples provided by CDIs tested positive for cocaine and all of the urine samples provided by the controls tested cocaine negative. The absence of acute alcohol intoxication was verified using breath tests. At the beginning of each session, a single dose of 40&#x000a0;mg atomoxetine or placebo was given orally and vital signs were measured. Participants were dosed either at 11.00 am or at 12.00 pm. After approximately 2&#x000a0;h, vital signs were measured again and blood samples taken to assess atomoxetine plasma concentrations. Finally, approximately 2.5&#x000a0;h after atomoxetine dosing, all volunteers performed the cognitive tests. This schedule was based on pharmacokinetics data declared in the Strattera&#x000ae; (atomoxetine hydrochloride) leaflet which reports that plasma concentration of atomoxetine peaks approximately 2&#x000a0;h after a single oral dose of 40&#x000a0;mg and remains at ~60% peak up to 6&#x000a0;h.</p></sec><sec id="Sec4"><title>Experimental tests</title><sec id="Sec5"><title>Line-counting task with cocaine-related and neutral pictures</title><p id="Par17">We employed a modified version of the paradigm originally developed by Luijten et al. (<xref ref-type="bibr" rid="CR33">2011</xref>), in which participants were asked to indicate, via a button-press response, the number of lines superimposed on photographic images displayed on the screen. Seventy-two coloured photographs, half depicting images of non-cocaine-related objects and activities (household items; individual handling household items) and the other half showing cocaine-related objects and activities (a crack pipe; individual smoking a crack pipe), were presented twice to participants. On each photograph, semi-randomly spaced blue horizontal lines were superimposed. The number of lines varied between 2 and 5, and participants had to respond by pressing the corresponding number keys on the keyboard. The images were matched across the two conditions (neutral, cocaine) for colour, brightness, object size, object position, and the number of blue lines laid over them.</p><p id="Par18">The task was administered in eight runs, each consisting of a block of nine neutral images and nine cocaine-related photographs. The order of the category to be shown first within a block (neutral or cocaine) was randomized to control for order effects. Each photograph was displayed in the centre of the computer screen for 900&#x000a0;msec and participants were asked to respond as soon as possible when the picture appeared on the screen. The inter-stimulus interval was jittered across trials and on average lasted 1750&#x000a0;msec. All participants were trained on the task with a practice run of 30 unrelated colour photographs (depicting animals, people, or landscapes) to familiarize themselves with the task and the response buttons.</p><p id="Par19">Attentional bias to cocaine-related pictures was quantified by an interference score, which was calculated as the mean latency of correct responses to the cocaine-related images minus the mean latency to correct responses to the non-cocaine-related images.</p></sec><sec id="Sec6"><title>Go/no-go task with cocaine-related and food-related words</title><p id="Par20">A modified version of a verbal go/no-go task previously developed by Noel et al. (<xref ref-type="bibr" rid="CR38">2005</xref>) was employed. The task included cocaine-related words and food-related words, each of which was displayed, one by one, in the middle of the screen. Half of the words were targets to which participants were instructed (via a visual cue) to respond as quickly as possible by pressing a button, and half of them were distracters to which participants had to refrain responding. Each word was presented for 500&#x000a0;msec, with an inter-stimulus interval of 900&#x000a0;msec between two words.</p><p id="Par21">Eighteen word stimuli (nine cocaine-related words and nine food-related words) were grouped in a block, and within each block, either cocaine- or food-related words were specified as targets. The cocaine- and food-related words were as closely matched as possible in terms of word length and frequency. Examples of cocaine-related words were &#x02018;amphetamine&#x02019;, &#x02018;crack&#x02019;, and &#x02018;dealer&#x02019;, whilst words like &#x02018;marshmallows&#x02019;, &#x02018;pizza&#x02019;, and &#x02018;cherry&#x02019; were used as food-related words. Whether participants started with cocaine-related or food-related words was randomized within each group. Reaction times (RTs) to respond to a target were calculated for all participants and RTs &#x0003c;100&#x000a0;msec (anticipated responses) were excluded from the analyses.</p><p id="Par22">As in a previous study (Sahgal <xref ref-type="bibr" rid="CR42">1987</xref>), we computed the number of false alarms (i.e. response to a distracter) and hits (correct response to a target) that were both used to calculate a response bias score. The response bias score was calculated as follows: response bias&#x000a0;=&#x000a0;&#x02212;0.5 &#x000d7; (<italic>Z</italic> (corrected probability of hits) + <italic>Z</italic> (corrected probability of false alarms)), where <italic>Z</italic> scores were calculated using the inverse phi function, which determines the <italic>Z</italic> score of <italic>P</italic> values. The corrected probability of hits was also computed as follows: corrected probability of hits = (number of correct go responses +0.5)/(total number of go trials +1) and the corrected probability of false alarms = (number of incorrect no-go responses +0.5)/(total number of no-go trials +1).</p><p id="Par23">Given that the response bias score takes into account both correct responses and false alarms, it can be considered a better indicator of impulsivity and disinhibition than false alarms alone (Sahgal <xref ref-type="bibr" rid="CR42">1987</xref>). A more negative response bias score reflects higher impulsivity (Noel et al. <xref ref-type="bibr" rid="CR38">2005</xref>).</p></sec></sec><sec id="Sec7"><title>Plasma analysis</title><p id="Par24">Plasma levels of atomoxetine were analysed in all participants, with a high-performance liquid chromatographic method (Agilent Technologies GmbH, Waldbronn, Germany). Separation of atomoxetine and mianserine (internal standard) was performed on an Agilent Zorbax Eclipse XDB C8 reversed phase column. Detection wavelength was 218&#x000a0;nm, and the limit of quantitation was 2.0&#x000a0;&#x003bc;g/l. Importantly, there were no any additional peaks in the samples indicative of atomoxetine metabolites.</p></sec><sec id="Sec8"><title>Statistical analyses</title><p id="Par25">Data were analysed using the SPSS (v.24) software. Independent two sample <italic>t</italic> tests were used for group comparisons on demographic, cognitive, and personality variables as well as vital signs (i.e. pulse, systolic, and diastolic blood pressure).</p><p id="Par26">Furthermore, the interference scores for the line-counting task and the response bias scores for the cocaine-related go/no-go task were entered in repeated-measure general linear models (GLM) that tested for (1) the main effect of group, (2) main effect of treatment, (3) main effect of stimulus (for the go/no-go task), and (4) any group &#x000d7; treatment interaction or group &#x000d7; stimulus and group &#x000d7; treatment &#x000d7; stimulus interaction (the latter two only for the go/no-go task). The main effect of and interactions involving the stimulus (cocaine, food) were only possible for the drug-related go/no-go task as the interference scores for the attentional bias task were calculated in terms of reaction times to cocaine-related minus neutral stimuli.</p><p id="Par27">Individual plasma levels of atomoxetine were correlated (using the Pearson&#x02019;s correlation coefficient) with (1) the difference in the interference measures during the attentional bias task (calculated by subtracting the interference scores during placebo from the same metrics under atomoxetine) and (2) the difference in the response bias scores during the cocaine-related go/no-go task (computed by subtracting the response bias indices during placebo from the same metrics under atomoxetine). Using repeated-measure GLM, we also assessed whether self-reported feelings of cocaine craving changed after each tasks and whether they were influenced by atomoxetine.</p><p id="Par28">Finally, the differences in the interference scores between atomoxetine and placebo conditions for the line-counting task as well as the differences for the response bias scores for the cocaine-related go/no-go paradigm were correlated with the BDI-II, BIS-11, and ASRS scores as well as with the number of years of cocaine use. All statistical tests performed were two-tailed and the significance level threshold was set at <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05.</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>Demographics, cognitive, and personality data</title><p id="Par29">The groups were well-matched in terms of gender and age (Table <xref rid="Tab1" ref-type="table">1</xref>). Furthermore, there were no differences between groups in pulse rate, systolic, or diastolic blood pressure suggesting that cocaine users were not acutely intoxicated (Table <xref rid="Tab1" ref-type="table">1</xref>). CDIs scored significantly higher on the BDI-II and BIS-11 questionnaires compared to controls (Table <xref rid="Tab1" ref-type="table">1</xref>). Self-reported feelings of cocaine craving did not increase significantly after the task (<italic>F</italic>1,25&#x000a0;=&#x000a0;1.83, <italic>P</italic>&#x000a0;=&#x000a0;0.18) and were not affected by atomoxetine (<italic>F</italic>1,25&#x000a0;=&#x000a0;0.59, <italic>P</italic>&#x000a0;=&#x000a0;0.44).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Demographics, cognitive, personality, and baseline characteristics of the sample</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Controls (<italic>n</italic>&#x000a0;=&#x000a0;28)</th><th>CDIs (<italic>n</italic>&#x000a0;=&#x000a0;28)</th><th>Group differences</th></tr></thead><tbody><tr><td>Age (years&#x000a0;&#x000b1;&#x000a0;SD)</td><td>44.7&#x000a0;&#x000b1;&#x000a0;7.4</td><td>41.1&#x000a0;&#x000b1;&#x000a0;7.4</td><td>
<italic>F</italic>&#x000a0;=&#x000a0;0.14, <italic>P</italic>&#x000a0;=&#x000a0;0.70</td></tr><tr><td>Gender (males/females)</td><td>26/2</td><td>27/1</td><td>NS</td></tr><tr><td>Education (years&#x000a0;&#x000b1;&#x000a0;SD)</td><td>12.8&#x000a0;&#x000b1;&#x000a0;2.8</td><td>11.5&#x000a0;&#x000b1;&#x000a0;1.8</td><td>
<italic>F</italic>&#x000a0;=&#x000a0;4.7, <italic>P</italic>&#x000a0;=&#x000a0;0.03</td></tr><tr><td>Verbal IQ, NART (mean scores&#x000a0;&#x000b1;&#x000a0;SD)</td><td>115.2&#x000a0;&#x000b1;&#x000a0;6.7</td><td>102.3&#x000a0;&#x000b1;&#x000a0;8.4</td><td>
<italic>F</italic>&#x000a0;=&#x000a0;0.94, <italic>P</italic>&#x000a0;=&#x000a0;0.33</td></tr><tr><td>Dysphoric mood, BDI-II (mean score&#x000a0;&#x000b1;&#x000a0;SD)</td><td>3.0&#x000a0;&#x000b1;&#x000a0;4.3</td><td>16.0&#x000a0;&#x000b1;&#x000a0;8.6</td><td>
<italic>F</italic>&#x000a0;=&#x000a0;13.2, <italic>P</italic>&#x000a0;=&#x000a0;0.001</td></tr><tr><td>Trait impulsivity. BIS-11 (mean score&#x000a0;&#x000b1;&#x000a0;SD)</td><td>58.4&#x000a0;&#x000b1;&#x000a0;6.8</td><td>72.9&#x000a0;&#x000b1;&#x000a0;9.9</td><td>
<italic>F</italic>&#x000a0;=&#x000a0;5.3, <italic>P</italic>&#x000a0;=&#x000a0;0.025</td></tr><tr><td>Trait anxiety, STAI (mean score&#x000a0;&#x000b1;&#x000a0;SD)</td><td>29.1&#x000a0;&#x000b1;&#x000a0;7.2</td><td>41.7&#x000a0;&#x000b1;&#x000a0;8.4</td><td>
<italic>F</italic>&#x000a0;=&#x000a0;36.7, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001</td></tr><tr><td>Adult ADHD self-report scale (ASRS)</td><td>40.7&#x000a0;&#x000b1;&#x000a0;8.3</td><td>48.4&#x000a0;&#x000b1;&#x000a0;9.5</td><td>
<italic>T</italic>&#x000a0;=&#x000a0;3.2, <italic>P</italic>&#x000a0;=&#x000a0;0.002</td></tr><tr><td>Pulse rate (ppm&#x000a0;&#x000b1;&#x000a0;SD)</td><td>67.3&#x000a0;&#x000b1;&#x000a0;11.8</td><td>70.6&#x000a0;&#x000b1;&#x000a0;12.0</td><td>
<italic>F</italic>&#x000a0;=&#x000a0;0.003, <italic>P</italic>&#x000a0;=&#x000a0;0.96</td></tr><tr><td>Systolic blood pressure (mmHg&#x000a0;&#x000b1;&#x000a0;SD)</td><td>121.2&#x000a0;&#x000b1;&#x000a0;11.5</td><td>120.9&#x000a0;&#x000b1;&#x000a0;14.3</td><td>
<italic>F</italic>&#x000a0;=&#x000a0;1.1, <italic>P</italic>&#x000a0;=&#x000a0;0.29</td></tr><tr><td>Diastolic blood pressure (mmHg&#x000a0;&#x000b1;&#x000a0;SD)</td><td>73.6&#x000a0;&#x000b1;&#x000a0;8.9</td><td>73.2&#x000a0;&#x000b1;&#x000a0;9.8</td><td>
<italic>F</italic>&#x000a0;=&#x000a0;0.26, <italic>P</italic>&#x000a0;=&#x000a0;0.60</td></tr><tr><td>Discrimination data (<italic>D</italic>&#x02032;) during the go/no-go task for the drug word stimuli (on atomoxetine)</td><td>2.7&#x000a0;&#x000b1;&#x000a0;0.8</td><td>1.8&#x000a0;&#x000b1;&#x000a0;1.0</td><td>
<italic>T</italic>&#x000a0;=&#x000a0;3.4, <italic>P</italic>&#x000a0;=&#x000a0;0.001</td></tr><tr><td>Discrimination data (<italic>D</italic>&#x02032;) during the go/no-go task for the drug word stimuli (under placebo)</td><td>2.7&#x000a0;&#x000b1;&#x000a0;0.8</td><td>1.8&#x000a0;&#x000b1;&#x000a0;0.8</td><td>
<italic>T</italic>&#x000a0;=&#x000a0;3.9, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001</td></tr><tr><td>Discrimination data (<italic>D</italic>&#x02032;) during the go/no-go task for the food word stimuli (on atomoxetine)</td><td>3.0&#x000a0;&#x000b1;&#x000a0;0.7</td><td>2.2&#x000a0;&#x000b1;&#x000a0;0.8</td><td>
<italic>T</italic>&#x000a0;=&#x000a0;3.9, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001</td></tr><tr><td>Discrimination data (<italic>D</italic>&#x02032;) during the go/no-go task for the word stimuli (under placebo)</td><td>2.9&#x000a0;&#x000b1;&#x000a0;0.7</td><td>1.9&#x000a0;&#x000b1;&#x000a0;0.8</td><td>
<italic>T</italic>&#x000a0;=&#x000a0;4.6, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001</td></tr></tbody></table><table-wrap-foot><p>The discrimination data during the go/no-go task were calculated using a signal detection analysis (<italic>D</italic>&#x02032;) (Snodgrass and Corwin <xref ref-type="bibr" rid="CR48">1988</xref>). <italic>D</italic>&#x02032;&#x000a0;&#x0003c;&#x000a0;or&#x000a0;=&#x000a0;0 indicates that participants were either unable to discriminate targets from distracters or they were not performing the task as instructed. A <italic>D</italic>&#x02032;&#x000a0;&#x0003e;&#x000a0;0 reflects good discrimination ability (e.g. more hits and less false alarms)</p><p>
<italic>SD</italic> standard deviation, <italic>CDIs</italic> cocaine-dependent individuals, <italic>IQ</italic> intelligence quotient, <italic>NART</italic> National Adult Reading Test, <italic>BDI-II</italic> Beck Depression Inventory-second edition, <italic>BIS-11</italic> Barratt Impulsiveness Scale-11, <italic>STAI</italic> Spielberger State-Trait Inventory, <italic>ppm</italic> pulse per minute, <italic>NS</italic> not significant by means of a <italic>&#x003c7;</italic>
<sup>2</sup> test</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec11"><title>Behavioural performance</title><sec id="Sec12"><title>Attentional bias during the line-counting task with cocaine-related and neutral pictures</title><p id="Par30">There was a significant main effect of group with increased interference scores in CDIs relative to controls, reflecting increased attentional bias to cocaine-related photographs in CDIs (<italic>F</italic>26&#x000a0;=&#x000a0;5.34, <italic>P</italic>&#x000a0;=&#x000a0;0.02) (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Whilst there was no significant main effect of treatment (<italic>F</italic>26&#x000a0;=&#x000a0;2.42, <italic>P</italic>&#x000a0;=&#x000a0;0.13), there was a significant group &#x000d7; treatment interaction (<italic>F</italic>26&#x000a0;=&#x000a0;6.73, <italic>P</italic>&#x000a0;=&#x000a0;0.01). Specifically, post hoc analyses showed that atomoxetine reduced the attentional bias to cocaine-related pictures in CDIs but there was no difference between atomoxetine and placebo in controls (Fig. <xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>This figure displays the differences between groups and treatment conditions in the interference measure (an index of attentional bias) that was calculated by subtracting the mean response latency during non-drug-related conditions (<italic>bottom right panel</italic> for an example) from the mean response latency during drug-related pictures presentation (<italic>top right panel</italic> for an example). Overall, there was a significant main effect of group that was driven by a generally increased attentional bias to drug-related cues in cocaine-dependent individuals relative to controls. More importantly, however, there was a significant group by treatment interaction that was dependent on the fact that atomoxetine administration reduced the attentional bias to drug-related pictures selectively in the cocaine group. <italic>Black circles</italic> represent the mean values per each group and treatment condition whilst the <italic>capped lines</italic> denote the standard errors</p></caption><graphic xlink:href="213_2017_4643_Fig1_HTML" id="MO1"/></fig>
</p></sec><sec id="Sec13"><title>Response inhibition during the go/no-go task with cocaine- and food-related words</title><p id="Par31">There was no main effect of group (<italic>F</italic>26&#x000a0;=&#x000a0;0.64, <italic>P</italic>&#x000a0;=&#x000a0;0.42) or treatment (<italic>F</italic>26&#x000a0;=&#x000a0;0.08, <italic>P</italic>&#x000a0;=&#x000a0;0.77), although we found a main effect of stimulus type which was driven by increased response bias to cocaine relative to food-related words (<italic>F</italic>26&#x000a0;=&#x000a0;6.37, <italic>P</italic>&#x000a0;=&#x000a0;0.01) (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). There was no significant group &#x000d7; treatment interaction (<italic>F</italic>26&#x000a0;=&#x000a0;0.15, <italic>P</italic>&#x000a0;=&#x000a0;0.69), although a trend towards statistical significance for the group &#x000d7; stimulus &#x000d7; treatment interaction was found (<italic>F</italic>26&#x000a0;=&#x000a0;3.38, <italic>P</italic>&#x000a0;=&#x000a0;0.07). A post hoc comparison between groups during the placebo condition was not statistically different (<italic>T</italic>&#x000a0;=&#x000a0;1.15, <italic>P</italic>&#x000a0;=&#x000a0;0.13) indicating that CDIs were not more impulsive than controls on baseline.<fig id="Fig2"><label>Fig. 2</label><caption><p>The plot displays the differences between groups, stimulus type, and treatment conditions in the response bias score (an indicator of impulsivity). Overall, atomoxetine reduced impulsive responding for drug-related target words and had the opposite effect when food-related words were the target, particularly in people with cocaine addiction</p></caption><graphic xlink:href="213_2017_4643_Fig2_HTML" id="MO2"/></fig>
</p></sec></sec><sec id="Sec14"><title>Correlational analyses</title><p id="Par32">No significant correlations were found between plasma atomoxetine levels and (1) the difference between interference scores under atomoxetine and the same measures under placebo for the attentional bias task and (2) the differences between response bias scores under atomoxetine and the same measures under placebo for the cocaine-related go/no-go task (Pearson&#x02019;s <italic>r</italic>&#x02019;s&#x000a0;&#x0003c;&#x000a0;0.19, <italic>P</italic>&#x02019;s&#x000a0;&#x0003e;&#x000a0;0.18 or <italic>r</italic>&#x02019;s&#x000a0;&#x0003e;&#x000a0;&#x02212;0.21, <italic>P</italic>&#x02019;s&#x000a0;&#x0003e;&#x000a0;0.11).</p><p id="Par33">On examining the relationship between the attentional bias to cocaine-related cues, response inhibition measures, and clinical as well as personality variables (i.e. years of cocaine use, BDI-II, BIS-11, and ASRS scores), we found that the difference in attentional bias measures between atomoxetine and placebo conditions was only (and positively) correlated with the years of cocaine use (Person&#x02019;s <italic>r</italic>&#x000a0;=&#x000a0;0.48, <italic>P</italic>&#x000a0;=&#x000a0;0.02). In other words, CDIs with the longest history of cocaine use gained the least benefit from atomoxetine in terms of reducing attentional bias to cocaine-related cues. However, excluding an individual with 5&#x000a0;years of cocaine use made this result of borderline significance (<italic>r</italic>&#x000a0;=&#x000a0;&#x02212;.38, <italic>P</italic>&#x000a0;=&#x000a0;0.08), so we no further discuss it.</p></sec></sec><sec id="Sec15"><title>Discussion</title><p id="Par34">We provide new evidence that atomoxetine significantly decreased attentional bias to cocaine-related stimuli in cocaine-dependent individuals (CDIs). Overall, these findings show that atomoxetine impacts on a key neurocognitive measure in cocaine addiction&#x02014;i.e. attentional bias to cocaine-related cues (Marhe et al. <xref ref-type="bibr" rid="CR34">2013</xref>; Marissen et al. <xref ref-type="bibr" rid="CR36">2006</xref>).</p><p id="Par35">Although the molecular mechanisms of the cognitive enhancing properties of atomoxetine require further investigation, a previous animal study has demonstrated that atomoxetine diminishes tonic firing of the locus coeruleus (LC) whilst leaving phasic bursting intact (Bari and Aston-Jones <xref ref-type="bibr" rid="CR3">2013</xref>). Together, these mechanisms are in keeping with the traditional theory of LC noradrenergic function which posits that performance on cognitive tasks is optimal at intermediate levels of tonic noradrenergic transmission but deteriorates when too little or too much noradrenaline is available (Aston-Jones et al. <xref ref-type="bibr" rid="CR2">1999</xref>; Bari and Aston-Jones <xref ref-type="bibr" rid="CR3">2013</xref>). In the context of our data, we speculate that atomoxetine may alter the balance between the tonic and phasic LC firing which overall reduces distractibility and attentional bias to cocaine-related cues in CDIs (Bari and Aston-Jones <xref ref-type="bibr" rid="CR3">2013</xref>). Conversely, atomoxetine did not influence task performance in controls as these persons already display an optimal range of noradrenaline transmission, and perhaps more importantly, as expected, they did not show attentional bias to cocaine-related cues. Consequently, it remains to be tested whether atomoxetine can also modulate other types of attentional bias in healthy individuals.</p><p id="Par36">In terms of likely terminal domains for the effects of atomoxetine, the drug increases noradrenaline levels in the prefrontal cortex (PFC) which in turn would enhance &#x02018;top-down&#x02019; cognitive control (Arnsten <xref ref-type="bibr" rid="CR1">2009</xref>). Atomoxetine has also been found to increase extracellular levels of dopamine as well as noradrenaline in the PFC (Bymaster et al. <xref ref-type="bibr" rid="CR9">2002</xref>) and so it is also possible that the present effects were mediated by PFC dopamine. However, a previous study reported that the effects of atomoxetine on response inhibitory control in rats were mediated by noradrenergic rather than dopaminergic neurotransmission (Bari et al. <xref ref-type="bibr" rid="CR5">2011</xref>). A non-mutually exclusive possibility is that atomoxetine simultaneously affects noradrenergic- and dopaminergic-related mechanisms which in turn act in concert to modulate specific PFC circuits mediating attentional control (Briand et al. <xref ref-type="bibr" rid="CR8">2007</xref>).</p><p id="Par37">In addition, we found a trend towards statistical significance (<italic>P</italic>&#x000a0;=&#x000a0;0.07) for the group &#x000d7; stimulus &#x000d7; treatment interaction during the go/no-go task. A post hoc comparison between groups during the placebo condition was not statistically different (<italic>T</italic>&#x000a0;=&#x000a0;1.15, <italic>P</italic>&#x000a0;=&#x000a0;0.13) indicating that CDIs were not more impulsive than controls on baseline. However, this result may warrant a replication with larger samples.</p><p id="Par38">Our findings suggest new avenues for future research, for example, to elucidate the brain mechanisms underlying the atomoxetine effects on attentional bias to cocaine-related cues using functional magnetic resonance imaging (fMRI). A previous fMRI study found that smokers, relative to non-smokers, showed greater dorsal anterior cingulate cortex (dACC) activity whilst attending to task-relevant information in the presence of distracting smoke-related cues (Luijten et al. <xref ref-type="bibr" rid="CR33">2011</xref>). This indicates that smokers excessively recruit the dACC to achieve the necessary attentional control for task performance. Increased dACC activation during a Stroop paradigm has also been found to predict relapse in cocaine use 3&#x000a0;months after detoxification (Marhe et al. <xref ref-type="bibr" rid="CR34">2013</xref>). Together, these results suggest that task-related brain function in specific regions could be a promising biomarker in people with substance dependence, although it remains to be elucidated whether it can be used to identify those CDIs most likely to benefit from pharmacological interventions such as atomoxetine.</p><p id="Par39">Although a previous clinical trial provided no support for the use of atomoxetine in treating cocaine dependence (Walsh et al. <xref ref-type="bibr" rid="CR49">2013</xref>), this null finding may have in part been due to the lack of reliable neurocognitive indices to stratify patients and to the use of pharmacological treatments which were limited in time. Hence, studies assessing the effects of chronic atomoxetine therapy to evaluate long-term changes in neurocognitive and behavioural outcome measures in selected groups of CDIs are warranted.</p></sec></body><back><ack><p>We thank all volunteers for their participation in this study, as well as the staff at the Mental Health Research Network and the Cambridge BioResource for their assistance with volunteer recruitment. We are grateful to the staff at the NIHR Clinical Research Facility at Addenbrooke&#x02019;s Hospital for their dedication and support throughout this study. We also thank Sanja Abbott, Jean Arlt, Claire Whitelock, Ilse Lee, and Miriam Pollard for their invaluable assistance. Thanks also go to Clare Popham for presenting the preliminary results at the 28th European College of Neuropsychopharmacology Congress in Amsterdam (NL) in September 2015.</p></ack><notes notes-type="COI-statement"><title>Compliance with ethical standards</title><p>The study was approved by the National Research Ethics Committee and all participants provided written informed consent.</p><sec id="FPar1"><title>Funding and disclosure</title><p id="Par40">This work was funded by a grant of the Medical Research Council (MR/J012084/1) to TWR, KDE, ETB, and BJS and conducted within the Behavioural and Clinical Neuroscience Institute at the University of Cambridge, which is jointly funded by the Medical Research Council and the Wellcome Trust. This study was jointly sponsored by the Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. TWR consults for Cambridge Cognition, Lundbeck, and Mundipharma and holds a research grant from Shionogi. ETB is employed part-time by GlaxoSmithKline and part-time by the University of Cambridge and serves as the Head of Research and Development at the Cambridgeshire and Peterborough National Health Service Foundation Trust. BS reports receiving consulting fees and lecture honoraria from Lundbeck, lecture honorarium from Servier, consulting fees from Cambridge Cognition, and a grant from Janssen/Johnson &#x00026; Johnson. All other authors report no biomedical financial interests or potential conflicts of interest. The trial name is &#x02018;Investigating the Effects of Atomoxetine on Brain and Behaviour&#x02019;. The trial URL is <ext-link ext-link-type="uri" xlink:href="http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=13999">http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=13999;</ext-link> the trial registration number is MREC No. 12/EE/0519 UKCRN ID 13999.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnsten</surname><given-names>AF</given-names></name></person-group><article-title>Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction</article-title><source>CNS Drugs</source><year>2009</year><volume>23</volume><issue>Suppl 1</issue><fpage>33</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.2165/00023210-200923000-00005</pub-id><pub-id pub-id-type="pmid">19621976</pub-id></element-citation></ref><ref id="CR2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aston-Jones</surname><given-names>G</given-names></name><name><surname>Rajkowski</surname><given-names>J</given-names></name><name><surname>Cohen</surname><given-names>J</given-names></name></person-group><article-title>Role of locus coeruleus in attention and behavioral flexibility</article-title><source>Biol Psychiatry</source><year>1999</year><volume>46</volume><fpage>1309</fpage><lpage>1320</lpage><pub-id pub-id-type="doi">10.1016/S0006-3223(99)00140-7</pub-id><pub-id pub-id-type="pmid">10560036</pub-id></element-citation></ref><ref id="CR3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bari</surname><given-names>A</given-names></name><name><surname>Aston-Jones</surname><given-names>G</given-names></name></person-group><article-title>Atomoxetine modulates spontaneous and sensory-evoked discharge of locus coeruleus noradrenergic neurons</article-title><source>Neuropharmacology</source><year>2013</year><volume>64</volume><fpage>53</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2012.07.020</pub-id><pub-id pub-id-type="pmid">22820275</pub-id></element-citation></ref><ref id="CR4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bari</surname><given-names>A</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name></person-group><article-title>Inhibition and impulsivity: behavioral and neural basis of response control</article-title><source>Prog Neurobiol</source><year>2013</year><volume>108</volume><fpage>44</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.pneurobio.2013.06.005</pub-id><pub-id pub-id-type="pmid">23856628</pub-id></element-citation></ref><ref id="CR5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bari</surname><given-names>A</given-names></name><name><surname>Mar</surname><given-names>AC</given-names></name><name><surname>Theobald</surname><given-names>DE</given-names></name><name><surname>Elands</surname><given-names>SA</given-names></name><name><surname>Oganya</surname><given-names>KC</given-names></name><name><surname>Eagle</surname><given-names>DM</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name></person-group><article-title>Prefrontal and monoaminergic contributions to stop-signal task performance in rats</article-title><source>J Neurosci</source><year>2011</year><volume>31</volume><fpage>9254</fpage><lpage>9263</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1543-11.2011</pub-id><pub-id pub-id-type="pmid">21697375</pub-id></element-citation></ref><ref id="CR6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosker</surname><given-names>WM</given-names></name><name><surname>Neuner</surname><given-names>I</given-names></name><name><surname>Shah</surname><given-names>NJ</given-names></name></person-group><article-title>The role of impulsivity in psychostimulant- and stress-induced dopamine release: review of human imaging studies</article-title><source>Neurosci Biobehav Rev</source><year>2017</year><volume>78</volume><fpage>82</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2017.04.008</pub-id><pub-id pub-id-type="pmid">28438467</pub-id></element-citation></ref><ref id="CR7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyer</surname><given-names>M</given-names></name><name><surname>Dickerson</surname><given-names>M</given-names></name></person-group><article-title>Attentional bias and addictive behaviour: automaticity in a gambling-specific modified Stroop task</article-title><source>Addiction</source><year>2003</year><volume>98</volume><fpage>61</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1046/j.1360-0443.2003.00219.x</pub-id><pub-id pub-id-type="pmid">12492756</pub-id></element-citation></ref><ref id="CR8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briand</surname><given-names>LA</given-names></name><name><surname>Gritton</surname><given-names>H</given-names></name><name><surname>Howe</surname><given-names>WM</given-names></name><name><surname>Young</surname><given-names>DA</given-names></name><name><surname>Sarter</surname><given-names>M</given-names></name></person-group><article-title>Modulators in concert for cognition: modulator interactions in the prefrontal cortex</article-title><source>Prog Neurobiol</source><year>2007</year><volume>83</volume><fpage>69</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.pneurobio.2007.06.007</pub-id><pub-id pub-id-type="pmid">17681661</pub-id></element-citation></ref><ref id="CR9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bymaster</surname><given-names>FP</given-names></name><name><surname>Katner</surname><given-names>JS</given-names></name><name><surname>Nelson</surname><given-names>DL</given-names></name><name><surname>Hemrick-Luecke</surname><given-names>SK</given-names></name><name><surname>Threlkeld</surname><given-names>PG</given-names></name><name><surname>Heiligenstein</surname><given-names>JH</given-names></name><name><surname>Morin</surname><given-names>SM</given-names></name><name><surname>Gehlert</surname><given-names>DR</given-names></name><name><surname>Perry</surname><given-names>KW</given-names></name></person-group><article-title>Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder</article-title><source>Neuropsychopharmacology</source><year>2002</year><volume>27</volume><fpage>699</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1016/S0893-133X(02)00346-9</pub-id><pub-id pub-id-type="pmid">12431845</pub-id></element-citation></ref><ref id="CR10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cane</surname><given-names>JE</given-names></name><name><surname>Sharma</surname><given-names>D</given-names></name><name><surname>Albery</surname><given-names>IP</given-names></name></person-group><article-title>The addiction Stroop task: examining the fast and slow effects of smoking and marijuana-related cues</article-title><source>J Psychopharmacol</source><year>2009</year><volume>23</volume><fpage>510</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1177/0269881108091253</pub-id><pub-id pub-id-type="pmid">18562413</pub-id></element-citation></ref><ref id="CR11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chamberlain</surname><given-names>SR</given-names></name><name><surname>Muller</surname><given-names>U</given-names></name><name><surname>Blackwell</surname><given-names>AD</given-names></name><name><surname>Clark</surname><given-names>L</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name><name><surname>Sahakian</surname><given-names>BJ</given-names></name></person-group><article-title>Neurochemical modulation of response inhibition and probabilistic learning in humans</article-title><source>Science</source><year>2006</year><volume>311</volume><fpage>861</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1126/science.1121218</pub-id><pub-id pub-id-type="pmid">16469930</pub-id></element-citation></ref><ref id="CR12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chamberlain</surname><given-names>SR</given-names></name><name><surname>Hampshire</surname><given-names>A</given-names></name><name><surname>Muller</surname><given-names>U</given-names></name><name><surname>Rubia</surname><given-names>K</given-names></name><name><surname>Del Campo</surname><given-names>N</given-names></name><name><surname>Craig</surname><given-names>K</given-names></name><name><surname>Regenthal</surname><given-names>R</given-names></name><name><surname>Suckling</surname><given-names>J</given-names></name><name><surname>Roiser</surname><given-names>JP</given-names></name><name><surname>Grant</surname><given-names>JE</given-names></name><name><surname>Bullmore</surname><given-names>ET</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name><name><surname>Sahakian</surname><given-names>BJ</given-names></name></person-group><article-title>Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study</article-title><source>Biol Psychiatry</source><year>2009</year><volume>65</volume><fpage>550</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2008.10.014</pub-id><pub-id pub-id-type="pmid">19026407</pub-id></element-citation></ref><ref id="CR13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>WM</given-names></name><name><surname>Fadardi</surname><given-names>JS</given-names></name><name><surname>Pothos</surname><given-names>EM</given-names></name></person-group><article-title>The addiction-stroop test: theoretical considerations and procedural recommendations</article-title><source>Psychol Bull</source><year>2006</year><volume>132</volume><fpage>443</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1037/0033-2909.132.3.443</pub-id><pub-id pub-id-type="pmid">16719569</pub-id></element-citation></ref><ref id="CR14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunning</surname><given-names>JP</given-names></name><name><surname>Parvaz</surname><given-names>MA</given-names></name><name><surname>Hajcak</surname><given-names>G</given-names></name><name><surname>Maloney</surname><given-names>T</given-names></name><name><surname>Alia-Klein</surname><given-names>N</given-names></name><name><surname>Woicik</surname><given-names>PA</given-names></name><name><surname>Telang</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>GJ</given-names></name><name><surname>Volkow</surname><given-names>ND</given-names></name><name><surname>Goldstein</surname><given-names>RZ</given-names></name></person-group><article-title>Motivated attention to cocaine and emotional cues in abstinent and current cocaine users&#x02014;an ERP study</article-title><source>Eur J Neurosci</source><year>2011</year><volume>33</volume><fpage>1716</fpage><lpage>1723</lpage><pub-id pub-id-type="doi">10.1111/j.1460-9568.2011.07663.x</pub-id><pub-id pub-id-type="pmid">21450043</pub-id></element-citation></ref><ref id="CR15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Economidou</surname><given-names>D</given-names></name><name><surname>Dalley</surname><given-names>JW</given-names></name><name><surname>Everitt</surname><given-names>BJ</given-names></name></person-group><article-title>Selective norepinephrine reuptake inhibition by atomoxetine prevents cue-induced heroin and cocaine seeking</article-title><source>Biol Psychiatry</source><year>2011</year><volume>69</volume><fpage>266</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2010.09.040</pub-id><pub-id pub-id-type="pmid">21109233</pub-id></element-citation></ref><ref id="CR16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ersche</surname><given-names>KD</given-names></name><name><surname>Bullmore</surname><given-names>ET</given-names></name><name><surname>Craig</surname><given-names>KJ</given-names></name><name><surname>Shabbir</surname><given-names>SS</given-names></name><name><surname>Abbott</surname><given-names>S</given-names></name><name><surname>Muller</surname><given-names>U</given-names></name><name><surname>Ooi</surname><given-names>C</given-names></name><name><surname>Suckling</surname><given-names>J</given-names></name><name><surname>Barnes</surname><given-names>A</given-names></name><name><surname>Sahakian</surname><given-names>BJ</given-names></name><name><surname>Merlo-Pich</surname><given-names>EV</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name></person-group><article-title>Influence of compulsivity of drug abuse on dopaminergic modulation of attentional bias in stimulant dependence</article-title><source>Arch Gen Psychiatry</source><year>2010</year><volume>67</volume><fpage>632</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2010.60</pub-id><pub-id pub-id-type="pmid">20530013</pub-id></element-citation></ref><ref id="CR17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ersche</surname><given-names>KD</given-names></name><name><surname>Jones</surname><given-names>PS</given-names></name><name><surname>Williams</surname><given-names>GB</given-names></name><name><surname>Turton</surname><given-names>AJ</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name><name><surname>Bullmore</surname><given-names>ET</given-names></name></person-group><article-title>Abnormal brain structure implicated in stimulant drug addiction</article-title><source>Science</source><year>2012</year><volume>335</volume><fpage>601</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1126/science.1214463</pub-id><pub-id pub-id-type="pmid">22301321</pub-id></element-citation></ref><ref id="CR18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Field</surname><given-names>M</given-names></name><name><surname>Marhe</surname><given-names>R</given-names></name><name><surname>Franken</surname><given-names>IH</given-names></name></person-group><article-title>The clinical relevance of attentional bias in substance use disorders</article-title><source>CNS Spectr</source><year>2014</year><volume>19</volume><fpage>225</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1017/S1092852913000321</pub-id><pub-id pub-id-type="pmid">23663386</pub-id></element-citation></ref><ref id="CR19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>First</surname><given-names>MB</given-names></name></person-group><article-title>The DSM series and experience with DSM-IV</article-title><source>Psychopathology</source><year>2002</year><volume>35</volume><fpage>67</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1159/000065121</pub-id><pub-id pub-id-type="pmid">12145486</pub-id></element-citation></ref><ref id="CR20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>H</given-names></name><name><surname>Sinha</surname><given-names>R</given-names></name></person-group><article-title>The role of guanfacine as a therapeutic agent to address stress-related pathophysiology in cocaine-dependent individuals</article-title><source>Adv Pharmacol</source><year>2014</year><volume>69</volume><fpage>217</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-420118-7.00006-8</pub-id><pub-id pub-id-type="pmid">24484979</pub-id></element-citation></ref><ref id="CR21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>H</given-names></name><name><surname>Sofuoglu</surname><given-names>M</given-names></name><name><surname>Sinha</surname><given-names>R</given-names></name></person-group><article-title>Guanfacine enhances inhibitory control and attentional shifting in early abstinent cocaine-dependent individuals</article-title><source>J Psychopharmacol</source><year>2015</year><volume>29</volume><fpage>312</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1177/0269881114562464</pub-id><pub-id pub-id-type="pmid">25567555</pub-id></element-citation></ref><ref id="CR22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franken</surname><given-names>IH</given-names></name><name><surname>Hendriksa</surname><given-names>VM</given-names></name><name><surname>van den Brink</surname><given-names>W</given-names></name></person-group><article-title>Initial validation of two opiate craving questionnaires the obsessive compulsive drug use scale and the desires for drug questionnaire</article-title><source>Addict Behav</source><year>2002</year><volume>27</volume><fpage>675</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1016/S0306-4603(01)00201-5</pub-id><pub-id pub-id-type="pmid">12201376</pub-id></element-citation></ref><ref id="CR23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>RZ</given-names></name><name><surname>Volkow</surname><given-names>ND</given-names></name></person-group><article-title>Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex</article-title><source>Am J Psychiatry</source><year>2002</year><volume>159</volume><fpage>1642</fpage><lpage>1652</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.159.10.1642</pub-id><pub-id pub-id-type="pmid">12359667</pub-id></element-citation></ref><ref id="CR24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>RZ</given-names></name><name><surname>Tomasi</surname><given-names>D</given-names></name><name><surname>Rajaram</surname><given-names>S</given-names></name><name><surname>Cottone</surname><given-names>LA</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Maloney</surname><given-names>T</given-names></name><name><surname>Telang</surname><given-names>F</given-names></name><name><surname>Alia-Klein</surname><given-names>N</given-names></name><name><surname>Volkow</surname><given-names>ND</given-names></name></person-group><article-title>Role of the anterior cingulate and medial orbitofrontal cortex in processing drug cues in cocaine addiction</article-title><source>Neuroscience</source><year>2007</year><volume>144</volume><fpage>1153</fpage><lpage>1159</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2006.11.024</pub-id><pub-id pub-id-type="pmid">17197102</pub-id></element-citation></ref><ref id="CR25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>RA</given-names></name><name><surname>DesLauriers</surname><given-names>C</given-names></name><name><surname>Burda</surname><given-names>A</given-names></name><name><surname>Johnson-Arbor</surname><given-names>K</given-names></name></person-group><article-title>Cocaine: history, social implications, and toxicity: a review</article-title><source>Semin Diagn Pathol</source><year>2009</year><volume>26</volume><fpage>10</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1053/j.semdp.2008.12.001</pub-id><pub-id pub-id-type="pmid">19292024</pub-id></element-citation></ref><ref id="CR26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graf</surname><given-names>H</given-names></name><name><surname>Abler</surname><given-names>B</given-names></name><name><surname>Freudenmann</surname><given-names>R</given-names></name><name><surname>Beschoner</surname><given-names>P</given-names></name><name><surname>Schaeffeler</surname><given-names>E</given-names></name><name><surname>Spitzer</surname><given-names>M</given-names></name><name><surname>Schwab</surname><given-names>M</given-names></name><name><surname>Gron</surname><given-names>G</given-names></name></person-group><article-title>Neural correlates of error monitoring modulated by atomoxetine in healthy volunteers</article-title><source>Biol Psychiatry</source><year>2011</year><volume>69</volume><fpage>890</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2010.10.018</pub-id><pub-id pub-id-type="pmid">21168122</pub-id></element-citation></ref><ref id="CR27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hester</surname><given-names>R</given-names></name><name><surname>Dixon</surname><given-names>V</given-names></name><name><surname>Garavan</surname><given-names>H</given-names></name></person-group><article-title>A consistent attentional bias for drug-related material in active cocaine users across word and picture versions of the emotional Stroop task</article-title><source>Drug Alcohol Depend</source><year>2006</year><volume>81</volume><fpage>251</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2005.07.002</pub-id><pub-id pub-id-type="pmid">16095852</pub-id></element-citation></ref><ref id="CR28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kessler</surname><given-names>RC</given-names></name><name><surname>Adler</surname><given-names>L</given-names></name><name><surname>Ames</surname><given-names>M</given-names></name><name><surname>Demler</surname><given-names>O</given-names></name><name><surname>Faraone</surname><given-names>S</given-names></name><name><surname>Hiripi</surname><given-names>E</given-names></name><name><surname>Howes</surname><given-names>MJ</given-names></name><name><surname>Jin</surname><given-names>R</given-names></name><name><surname>Secnik</surname><given-names>K</given-names></name><name><surname>Spencer</surname><given-names>T</given-names></name><name><surname>Ustun</surname><given-names>TB</given-names></name><name><surname>Walters</surname><given-names>EE</given-names></name></person-group><article-title>The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population</article-title><source>Psychol Med</source><year>2005</year><volume>35</volume><fpage>245</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1017/S0033291704002892</pub-id><pub-id pub-id-type="pmid">15841682</pub-id></element-citation></ref><ref id="CR29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kratochvil</surname><given-names>CJ</given-names></name><name><surname>Vaughan</surname><given-names>BS</given-names></name><name><surname>Harrington</surname><given-names>MJ</given-names></name><name><surname>Burke</surname><given-names>WJ</given-names></name></person-group><article-title>Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder</article-title><source>Expert Opin Pharmacother</source><year>2003</year><volume>4</volume><fpage>1165</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1517/14656566.4.7.1165</pub-id><pub-id pub-id-type="pmid">12831341</pub-id></element-citation></ref><ref id="CR30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapeyre-Mestre</surname><given-names>M</given-names></name><name><surname>Dupui</surname><given-names>M</given-names></name></person-group><article-title>Drug abuse monitoring: which pharmacoepidemiological resources at the European level?</article-title><source>Therapie</source><year>2015</year><volume>70</volume><fpage>147</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.2515/therapie/2015006</pub-id><pub-id pub-id-type="pmid">25858571</pub-id></element-citation></ref><ref id="CR31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leeman</surname><given-names>RF</given-names></name><name><surname>Robinson</surname><given-names>CD</given-names></name><name><surname>Waters</surname><given-names>AJ</given-names></name><name><surname>Sofuoglu</surname><given-names>M</given-names></name></person-group><article-title>A critical review of the literature on attentional bias in cocaine use disorder and suggestions for future research</article-title><source>Exp Clin Psychopharmacol</source><year>2014</year><volume>22</volume><fpage>469</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1037/a0037806</pub-id><pub-id pub-id-type="pmid">25222545</pub-id></element-citation></ref><ref id="CR32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>FR</given-names></name><name><surname>Mariani</surname><given-names>JJ</given-names></name><name><surname>Secora</surname><given-names>A</given-names></name><name><surname>Brooks</surname><given-names>D</given-names></name><name><surname>Cheng</surname><given-names>WY</given-names></name><name><surname>Bisaga</surname><given-names>A</given-names></name><name><surname>Nunes</surname><given-names>E</given-names></name><name><surname>Aharonovich</surname><given-names>E</given-names></name><name><surname>Raby</surname><given-names>W</given-names></name><name><surname>Hennessy</surname><given-names>G</given-names></name></person-group><article-title>Atomoxetine treatment for cocaine abuse and adult attention-deficit hyperactivity disorder (ADHD): a preliminary open trial</article-title><source>J Dual Diagn</source><year>2009</year><volume>5</volume><fpage>41</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1080/15504260802628767</pub-id><pub-id pub-id-type="pmid">19430599</pub-id></element-citation></ref><ref id="CR33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luijten</surname><given-names>M</given-names></name><name><surname>Veltman</surname><given-names>DJ</given-names></name><name><surname>van den Brink</surname><given-names>W</given-names></name><name><surname>Hester</surname><given-names>R</given-names></name><name><surname>Field</surname><given-names>M</given-names></name><name><surname>Smits</surname><given-names>M</given-names></name><name><surname>Franken</surname><given-names>IH</given-names></name></person-group><article-title>Neurobiological substrate of smoking-related attentional bias</article-title><source>NeuroImage</source><year>2011</year><volume>54</volume><fpage>2374</fpage><lpage>2381</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2010.09.064</pub-id><pub-id pub-id-type="pmid">20932921</pub-id></element-citation></ref><ref id="CR34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marhe</surname><given-names>R</given-names></name><name><surname>Luijten</surname><given-names>M</given-names></name><name><surname>van de Wetering</surname><given-names>BJ</given-names></name><name><surname>Smits</surname><given-names>M</given-names></name><name><surname>Franken</surname><given-names>IH</given-names></name></person-group><article-title>Individual differences in anterior cingulate activation associated with attentional bias predict cocaine use after treatment</article-title><source>Neuropsychopharmacology</source><year>2013</year><volume>38</volume><fpage>1085</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.1038/npp.2013.7</pub-id><pub-id pub-id-type="pmid">23303067</pub-id></element-citation></ref><ref id="CR35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marhe</surname><given-names>R</given-names></name><name><surname>Luijten</surname><given-names>M</given-names></name><name><surname>Franken</surname><given-names>IH</given-names></name></person-group><article-title>The clinical relevance of neurocognitive measures in addiction</article-title><source>Front Psychiatry</source><year>2014</year><volume>4</volume><fpage>185</fpage><pub-id pub-id-type="doi">10.3389/fpsyt.2013.00185</pub-id><pub-id pub-id-type="pmid">24454294</pub-id></element-citation></ref><ref id="CR36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marissen</surname><given-names>MA</given-names></name><name><surname>Franken</surname><given-names>IH</given-names></name><name><surname>Waters</surname><given-names>AJ</given-names></name><name><surname>Blanken</surname><given-names>P</given-names></name><name><surname>van den Brink</surname><given-names>W</given-names></name><name><surname>Hendriks</surname><given-names>VM</given-names></name></person-group><article-title>Attentional bias predicts heroin relapse following treatment</article-title><source>Addiction</source><year>2006</year><volume>101</volume><fpage>1306</fpage><lpage>1312</lpage><pub-id pub-id-type="doi">10.1111/j.1360-0443.2006.01498.x</pub-id><pub-id pub-id-type="pmid">16911730</pub-id></element-citation></ref><ref id="CR37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nandam</surname><given-names>LS</given-names></name><name><surname>Hester</surname><given-names>R</given-names></name><name><surname>Wagner</surname><given-names>J</given-names></name><name><surname>Cummins</surname><given-names>TD</given-names></name><name><surname>Garner</surname><given-names>K</given-names></name><name><surname>Dean</surname><given-names>AJ</given-names></name><name><surname>Kim</surname><given-names>BN</given-names></name><name><surname>Nathan</surname><given-names>PJ</given-names></name><name><surname>Mattingley</surname><given-names>JB</given-names></name><name><surname>Bellgrove</surname><given-names>MA</given-names></name></person-group><article-title>Methylphenidate but not atomoxetine or citalopram modulates inhibitory control and response time variability</article-title><source>Biol Psychiatry</source><year>2011</year><volume>69</volume><fpage>902</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2010.11.014</pub-id><pub-id pub-id-type="pmid">21193172</pub-id></element-citation></ref><ref id="CR38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noel</surname><given-names>X</given-names></name><name><surname>Van der Linden</surname><given-names>M</given-names></name><name><surname>d&#x02019;Acremont</surname><given-names>M</given-names></name><name><surname>Colmant</surname><given-names>M</given-names></name><name><surname>Hanak</surname><given-names>C</given-names></name><name><surname>Pelc</surname><given-names>I</given-names></name><name><surname>Verbanck</surname><given-names>P</given-names></name><name><surname>Bechara</surname><given-names>A</given-names></name></person-group><article-title>Cognitive biases toward alcohol-related words and executive deficits in polysubstance abusers with alcoholism</article-title><source>Addiction</source><year>2005</year><volume>100</volume><fpage>1302</fpage><lpage>1309</lpage><pub-id pub-id-type="doi">10.1111/j.1360-0443.2005.01125.x</pub-id><pub-id pub-id-type="pmid">16128719</pub-id></element-citation></ref><ref id="CR39"><mixed-citation publication-type="other">Pintzinger NM, Pfabigan DM, Pfau L, Kryspin-Exner I, Lamm C (2016) Temperament differentially influences early information processing in men and women: preliminary electrophysiological evidence of attentional biases in healthy individuals. Biol Psychol</mixed-citation></ref><ref id="CR40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robbins</surname><given-names>TW</given-names></name><name><surname>Gillan</surname><given-names>CM</given-names></name><name><surname>Smith</surname><given-names>DG</given-names></name><name><surname>de Wit</surname><given-names>S</given-names></name><name><surname>Ersche</surname><given-names>KD</given-names></name></person-group><article-title>Neurocognitive endophenotypes of impulsivity and compulsivity: towards dimensional psychiatry</article-title><source>Trends Cogn Sci</source><year>2012</year><volume>16</volume><fpage>81</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.tics.2011.11.009</pub-id><pub-id pub-id-type="pmid">22155014</pub-id></element-citation></ref><ref id="CR41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>F</given-names></name></person-group><article-title>Attentional bias and alcohol dependence: a controlled study using the modified stroop paradigm</article-title><source>Addict Behav</source><year>2002</year><volume>27</volume><fpage>471</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1016/S0306-4603(01)00183-6</pub-id><pub-id pub-id-type="pmid">12188586</pub-id></element-citation></ref><ref id="CR42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahgal</surname><given-names>A</given-names></name></person-group><article-title>Some limitations of indices derived from signal detection theory: evaluation of an alternative index for measuring bias in memory tasks</article-title><source>Psychopharmacology</source><year>1987</year><volume>91</volume><fpage>517</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1007/BF00216022</pub-id><pub-id pub-id-type="pmid">3108933</pub-id></element-citation></ref><ref id="CR43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>KT</given-names></name><name><surname>Weinshenker</surname><given-names>D</given-names></name></person-group><article-title>Adrenaline rush: the role of adrenergic receptors in stimulant-induced behaviors</article-title><source>Mol Pharmacol</source><year>2014</year><volume>85</volume><fpage>640</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1124/mol.113.090118</pub-id><pub-id pub-id-type="pmid">24499709</pub-id></element-citation></ref><ref id="CR44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>R</given-names></name><name><surname>Luthold</surname><given-names>P</given-names></name><name><surname>Kittel</surname><given-names>R</given-names></name><name><surname>Tetzlaff</surname><given-names>A</given-names></name><name><surname>Hilbert</surname><given-names>A</given-names></name></person-group><article-title>Visual attentional bias for food in adolescents with binge-eating disorder</article-title><source>J Psychiatr Res</source><year>2016</year><volume>80</volume><fpage>22</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychires.2016.05.016</pub-id><pub-id pub-id-type="pmid">27267318</pub-id></element-citation></ref><ref id="CR45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheehan</surname><given-names>DV</given-names></name><name><surname>Lecrubier</surname><given-names>Y</given-names></name><name><surname>Sheehan</surname><given-names>KH</given-names></name><name><surname>Amorim</surname><given-names>P</given-names></name><name><surname>Janavs</surname><given-names>J</given-names></name><name><surname>Weiller</surname><given-names>E</given-names></name><name><surname>Hergueta</surname><given-names>T</given-names></name><name><surname>Baker</surname><given-names>R</given-names></name><name><surname>Dunbar</surname><given-names>GC</given-names></name></person-group><article-title>The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10</article-title><source>J Clin Psychiatry</source><year>1998</year><volume>59</volume><issue>Suppl 20</issue><fpage>22</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">9881538</pub-id></element-citation></ref><ref id="CR46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>RJ</given-names></name><name><surname>Aston-Jones</surname><given-names>G</given-names></name></person-group><article-title>Alpha(2) adrenergic and imidazoline receptor agonists prevent cue-induced cocaine seeking</article-title><source>Biol Psychiatry</source><year>2011</year><volume>70</volume><fpage>712</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2011.06.010</pub-id><pub-id pub-id-type="pmid">21783176</pub-id></element-citation></ref><ref id="CR47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>DG</given-names></name><name><surname>Jones</surname><given-names>PS</given-names></name><name><surname>Bullmore</surname><given-names>ET</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name><name><surname>Ersche</surname><given-names>KD</given-names></name></person-group><article-title>Cognitive control dysfunction and abnormal frontal cortex activation in stimulant drug users and their biological siblings</article-title><source>Transl Psychiatry</source><year>2013</year><volume>3</volume><fpage>e257</fpage><pub-id pub-id-type="doi">10.1038/tp.2013.32</pub-id><pub-id pub-id-type="pmid">23673468</pub-id></element-citation></ref><ref id="CR48"><mixed-citation publication-type="other">Snodgrass JG, Corwin J (1988) Pragmatics of measuring recognition memory: applications to dementia and amnesia. J Exp Psychol Gen 117(1):34&#x02013;50</mixed-citation></ref><ref id="CR49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>SL</given-names></name><name><surname>Middleton</surname><given-names>LS</given-names></name><name><surname>Wong</surname><given-names>CJ</given-names></name><name><surname>Nuzzo</surname><given-names>PA</given-names></name><name><surname>Campbell</surname><given-names>CL</given-names></name><name><surname>Rush</surname><given-names>CR</given-names></name><name><surname>Lofwall</surname><given-names>MR</given-names></name></person-group><article-title>Atomoxetine does not alter cocaine use in cocaine dependent individuals: double blind randomized trial</article-title><source>Drug Alcohol Depend</source><year>2013</year><volume>130</volume><fpage>150</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2012.10.024</pub-id><pub-id pub-id-type="pmid">23200303</pub-id></element-citation></ref><ref id="CR50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waters</surname><given-names>AJ</given-names></name><name><surname>Marhe</surname><given-names>R</given-names></name><name><surname>Franken</surname><given-names>IH</given-names></name></person-group><article-title>Attentional bias to drug cues is elevated before and during temptations to use heroin and cocaine</article-title><source>Psychopharmacology</source><year>2012</year><volume>219</volume><fpage>909</fpage><lpage>921</lpage><pub-id pub-id-type="doi">10.1007/s00213-011-2424-z</pub-id><pub-id pub-id-type="pmid">21833505</pub-id></element-citation></ref><ref id="CR51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiessing</surname><given-names>L</given-names></name></person-group><article-title>European drugs agency highlights trends in drug use and problems affecting drug users</article-title><source>Euro Surveill</source><year>2005</year><volume>10</volume><fpage>E051215 3</fpage><pub-id pub-id-type="pmid">16794294</pub-id></element-citation></ref></ref-list></back></article>